Trial Profile
Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 05 Mar 2021
Price :
$35
*
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Hypersomnia; Narcolepsy
- Focus Therapeutic Use
- 02 Mar 2021 Planned End Date changed from 31 Dec 2020 to 1 Sep 2020.
- 02 Mar 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Sep 2020.
- 02 Mar 2021 Status changed from recruiting to discontinued as target study population was extremely difficult to recruit and planned study budget was exceeded.